Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

Lindor, Keith D., Kowdley, Kris V., Heathcote, Jenny E., Harrison, Edwyn M., Jorgensen, Roberta, Angulo, Paul, Lymp, James F., Burgart, Lawrence +1 more·2004·Hepatology
DOI 10.1002/hep.20092

Cited by (727)

Items 101–200 of 727

  1. The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts
    Shuang Liang, T. Kisseleva, D. Brenner · 2016 · Frontiers in Physiology
  2. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease
    Paul Angulo, Laura M. Alba, Lydia M. Petrovic, Leon Anton Adams, Keith D. Lindor, Michael D. Jensen · 2004 · Journal of Hepatology
  3. Non‐alcoholic fatty liver disease from pathogenesis to management: an update
    Giovanni Musso, Roberto Gambino, Maurizio Cassader · 2009 · Obesity Reviews
  4. Non-alcoholic steatohepatitis: From cell biology to clinical practice
    Helena Cortez‐Pinto, Miguel Carneiro de Moura, Christopher Paul Day · 2005 · Journal of Hepatology
  5. A pilot study of orlistat treatment in obese, non‐alcoholic steatohepatitis patients
    Stephen A. Harrison, Chris Fincke, D. Helinski, Sigurd Torgerson, Paul Hideyo Hayashi · 2004 · Alimentary Pharmacology & Therapeutics
  6. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment
    Tim C. M. A. Schreuder, Bart J. Verwer, Carin MJ van Nieuwkerk, Chris Jacob Johan Mulder · 2008 · World Journal of Gastroenterology
  7. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
    Simona Marchisello, Antonino Di Pino, Roberto Scicali, Francesca Urbano, Salvatore Piro, Francesco Purrello, Agata Maria Rabuazzo · 2019 · International Journal of Molecular Sciences
  8. Nonalcoholic fatty liver disease
    Marcin Jan Krawczyk, Leonilde Bonfrate, Piero Portincasa · 2010 · Best Practice & Research Clinical Gastroenterology
  9. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology
    Ajay Kumar. Duseja, Shivaram Prasad Singh, Vivek A. Saraswat, Subrat Kumar Acharya, Yogesh Kumar Chawla, Subhankar Chowdhury, Radha Krishan Dhiman, Rohinivilasam Vasukutty Jayakumar, Kaushal Madan, Sri P. Misra et al. · 2015 · Journal of Clinical and Experimental Hepatology
  10. Nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Kenneth J. Cusi · 2009 · Current Opinion in Endocrinology Diabetes and Obesity
  11. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease
    G. Masterton, John N. Plevris, Peter Clive Hayes · 2009 · Alimentary Pharmacology & Therapeutics
  12. Non-alcoholic fatty liver disease in 2015
    Monjur Ahmed∥ · 2015 · World Journal of Hepatology
  13. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease
    Mitsuyoshi, Hironori, Yasui, Kohichiroh, Harano, Yuichi, Endo, Mio, Tsuji, Kazuhiro, Minami, Masahito, Itoh, Yoshito, Okanoue, Takeshi, Yoshikawa, Toshikazu · 2009 · Hepatology Research
  14. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design
    Naga Chalasani, Arun Jayant Sanyal, Kris V. Kowdley, Patricia R. Robuck, Jay H. Hoofnagle, David Erwin Kleiner, Aynur Ünalp, James A. Tonascia · 2008 · Contemporary Clinical Trials
  15. Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
    Zobair M. Younossi · 2008 · Alimentary Pharmacology & Therapeutics
  16. Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease
    Don C. Rockey · 2008 · Clinics in Liver Disease
  17. Bile salts and cholestasis
    Lucas J. Maillette de Buy Wenniger, Ulrich H. Beuers · 2010 · Digestive and Liver Disease
  18. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
    Yoshihisa Takahashi · 2015 · World Journal of Gastroenterology
  19. Non-alcoholic fatty liver disease: current concepts and management strategies
    David Adams, Geoffrey H. Haydon, Chris Day · 2006 · Clinical Medicine
  20. Nonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
    Romina Lomonaco, Nishanth E. Sunny, Fernando Bril, Kenneth J. Cusi · 2013 · Drugs
  21. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial
    Carly S. Eckard, Renee E. Cole, Joshua Lockwood, Dawn McDowell Torres, Christopher David Williams, Janet C. Shaw, Stephen A. Harrison · 2013 · Therapeutic Advances in Gastroenterology
  22. Significant correlations between severe fatty liver and risk factors for metabolic syndrome
    Pi‐Jung Hsiao, Kung‐Kai Kuo, Shyi‐Jang Shin, Yi‐Hsin Yang, Wen‐Yi Lin, Jeng‐Fu Yang, Chao‐Chin Chiu, Wan‐Long Chuang, Tong‐Rong Tsai, Ming‐Lung Yu · 2006 · Journal of Gastroenterology and Hepatology
  23. Review article: epidemiology, pathogenesis and potential treatments of paediatric non‐alcoholic fatty liver disease
    Nicole J Barshop, Claude B. Sirlin, Jeffrey B. Schwimmer, Joel E. Lavine · 2008 · Alimentary Pharmacology & Therapeutics
  24. Revision and update on clinical practice guideline for liver cirrhosis
    Ki Tae Suk, Soon Koo Baik, Jung‐Hwan Yoon, Jae Youn Cheong, Yong Han Paik, Chang Hyeong Lee, Young Seok Kim, Jin Woo Lee, Dong Joon Kim, Sung Won Cho et al. · 2012 · The Korean Journal of Hepatology
  25. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease
    Myeong Jun Song, Harmeet Malhi · 2019 · Pharmacology & Therapeutics
  26. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Monica D. Chow, Yi‐Horng Lee, Grace Liejun Guo · 2017 · Molecular Aspects of Medicine
  27. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
    Katsutoshi Tokushige, Kenichi Ikejima, Masafumi Ono, Yuichiro Eguchi, Yoshihiro Kamada, Yoshito Itoh, Norio Akuta, Masato Yoneda, Motoh Iwasa, Masashi Yoneda et al. · 2021 · Hepatology Research
  28. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial
    William Shields, Kari Thompson, G.A. Grice, Stephen A. Harrison, W. J. Coyle · 2009 · Therapeutic Advances in Gastroenterology
  29. The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review
    Zun Xiang, Yipeng Chen, Han Ma, Yue-fang Ye, Lin Zheng, Yida Yang, Youming Li, Xi Jin · 2013 · BMC Gastroenterology
  30. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
    Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun K. Takyar, Yaron Rotman, Ohad Etzion, Eric A Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop et al. · 2018 · Clinical Gastroenterology and Hepatology
  31. Clinical approaches to non-alcoholic fatty liver disease
    Katherine J. P. Schwenger · 2014 · World Journal of Gastroenterology
  32. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
    Stephen A. Harrison, Nadege Gunn, Guy W. Neff, Anita Kohli, Liping Liu, Abbey Flyer, Lawrence Goldkind, Adrian M. Di Bisceglie · 2021 · Nature Communications
  33. Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus
    Keith G. Tolman, Vivian Andrew Fonseca, Meng Hee Tan, Anthony S. Dalpiaz · 2004 · Annals of Internal Medicine
  34. Diabetes and liver disease: An ominous association
    Simona Moscatiello, Rita Manini, Giulio Marchesini · 2006 · Nutrition Metabolism and Cardiovascular Diseases
  35. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
    Hyun-Mi Kim, Da Som Lee, Tae Hyeon An, Hyun‐Ju Park, Won Kon Kim, Kwang‐Hee Bae, Kyoung‐Jin Oh · 2021 · International Journal of Molecular Sciences
  36. Pediatric Nonalcoholic Fatty Liver Disease in 2009
    Anna Alisi, Melania Manco, Andrea Vania, Valério Nobili · 2009 · The Journal of Pediatrics
  37. NASH and HCC
    John M. Page, Stephen A. Harrison · 2009 · Clinics in Liver Disease
  38. Update on non-alcoholic fatty liver disease in children
    Dimitrios Papandreou, Israel Rousso, Ioannis Mavromichalis · 2007 · Clinical Nutrition
  39. FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
    Rotonya M. Carr, Andrea Ewing Reid · 2015 · Current Atherosclerosis Reports
  40. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment
    Nathalie Carvalho Leite · 2014 · World Journal of Gastroenterology
  41. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis
    Juan Du · 2014 · World Journal of Gastroenterology
  42. Nonalcoholic fatty liver disease in the pediatric population: a review
    Anna Wieckowska, Ariel E. Feldstein · 2005 · Current Opinion in Pediatrics
  43. Mechanisms and clinical implications of hepatocyte lipoapoptosis
    Sophie C. Cazanave, Gregory James Gores · 2010 · Clinical Lipidology
  44. Ursodeoxycholic acid: Mechanism of action and novel clinical applications
    Tadashi Ikegami, Yasushi Matsuzaki · 2007 · Hepatology Research
  45. Nonalcoholic steatohepatitis
    Jörn Markus Schattenberg, Detlef Schuppan · 2011 · Current Opinion in Lipidology
  46. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
    Tingying Jiao, Yuandi Ma, Xiaozhen Guo, Yun‐Fei Ye, Cen Xie · 2022 · Acta Pharmacologica Sinica
  47. Treatment of non-alcoholic fatty liver disease.
    2007 · PubMed Central
  48. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial
    Leon Anton Adams, Dorothy H. Crawford, Katherine Anne Stuart, Michael J. House, Timothy G. St. Pierre, Malcolm Webb, Helena L. Ching, Jenny Kava, Michael Bynevelt, Gerry C. MacQuillan et al. · 2014 · Hepatology
  49. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
    Stephen A. Harrison, Brent A. Neuschwander‐Tetri · 2004 · Clinics in Liver Disease
  50. The evolving role of liver biopsy
    Mical S. Campbell, K. Rajender Reddy · 2004 · Alimentary Pharmacology & Therapeutics
  51. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
    Francesco Angelico, Marco Burattin, Cesare Alessandri, Maria Del Ben, Flavio Lirussi · 2007 · Cochrane Database of Systematic Reviews · Retracted
  52. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
    2013 · Clinical and Molecular Hepatology
  53. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Eugen Florin Georgescu, Marius Georgescu · 2007 · PubMed
  54. The Clinicopathological Profile of Indian Patients with Nonalcoholic Fatty Liver Disease (NAFLD) is Different from That in the West
    Ajay Kumar. Duseja, Ashim Das, Reena Das, Radha Krishan Dhiman, Yogesh Kumar Chawla, Anil Kumar Bhansali, Naveen Kalra · 2007 · Digestive Diseases and Sciences
  55. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota
    Michael Doulberis, Georgios Kotronis, Dimitra Gialamprinou, Jannis Kountouras, Panagiotis Katsinelos · 2017 · Metabolism
  56. Antifibrotic therapy in chronic liver disease
    Don C. Rockey · 2005 · Clinical Gastroenterology and Hepatology
  57. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
    Rafeeq Ali, Kenneth J. Cusi · 2009 · Annals of Medicine
  58. Combination of N ‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis
    Claudia Pinto Marques Souza de Oliveira, José Tadeu Stefano, Érika Rabelo Forte de Siqueira, Leonardo Soares Silva, Daniel Ferraz de Campos Mazo, Vicência Mara Rodrigues de Lima, Carlos Kiyoshi Furuya Junior, Evandro Sobroza de Mello, Fabricio Souza, Fabíola Rabelo et al. · 2007 · Hepatology Research
  59. Nonalcoholic fatty liver disease: Update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine
    Mazen Noureddin, José María Mato, Shelly Chi-Loo Lu · 2015 · Experimental Biology and Medicine
  60. The Unfolded Protein Response in Fatty Liver Disease
    Richard R. Green, Anne S. Henkel · 2013 · Seminars in Liver Disease
  61. Review: Treatment options for nonalcoholic fatty liver disease
    Brian P Lam, Zobair M. Younossi · 2010 · Therapeutic Advances in Gastroenterology
  62. Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease
    Chao Sun, Jian‐Gao Fan, Liang Qiao · 2015 · International Journal of Molecular Sciences
  63. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease
    VILAR GOMEZ, E., RODRIGUEZ DE MIRANDA, A., GRA ORAMAS, B., ARUS SOLER, E., LLANIO NAVARRO, R., CALZADILLA BERTOT, L., YASELLS GARCIA, A., DEL ROSARIO ABREU VAZQUEZ, M. · 2009 · Alimentary Pharmacology & Therapeutics
  64. Endoplasmic reticulum stress and the development of endothelial dysfunction.
    Micah L. Battson, Dustin M. Lee, C. Gentile · 2017 · American Journal of Physiology. Heart and Circulatory Physiology
  65. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non‐alcoholic fatty liver disease
    Marina G. Silveira, Flavia D. Mendes, Nancy N. Diehl, Felicity Enders, Keith D. Lindor · 2009 · Liver International
  66. Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review
    Piotr Socha, Andrea Horvath, Pietro Vajro, Piotr Dziechciarz, Anil Kumar Dhawan, Hania Szajewska · 2009 · Journal of Pediatric Gastroenterology and Nutrition
  67. Non-alcoholic fatty liver disease and cardiovascular risk
    Ángel Brea, José Puzo · 2012 · International Journal of Cardiology
  68. Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins
    Sofie M. A. Walenbergh, Ger H. Koek, Veerle Bieghs, Ronit Shiri‐Sverdlov · 2012 · Journal of Hepatology
  69. Pharmacological management of nonalcoholic fatty liver disease
    Barb, Diana, Portillo-Sanchez, Paola, Cusi, Kenneth · 2016 · Metabolism
  70. Current therapeutic strategies in non‐alcoholic fatty liver disease
    J. K. Dowman, Matthew James Armstrong, Jeremy Tomlinson, Philip Noel Newsome · 2011 · Diabetes Obesity and Metabolism
  71. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions
    Ajay Kumar. Duseja, Ashim Das, Radha Krishan Dhiman, Yogesh Kumar Chawla, Kiran Kumar Thumburu, Sanjay Kumar Bhadada, Anil Kumar Bhansali · 2007 · Annals of Hepatology
  72. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis
    Elizabeth M. Brunt · 2005 · Seminars in Diagnostic Pathology
  73. Endoplasmic Reticulum Stress and the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease
    Christopher L. Gentile, Melinda A. Frye, Michael J. Pagliassotti · 2010 · Antioxidants and Redox Signaling
  74. Feline hepatic lipidosis
    Sharon A. Center · 2005 · Veterinary Clinics of North America Small Animal Practice
  75. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages
    Veerle Bieghs, Patrick C.N. Rensen, Marten H. Hofker, Ronit Shiri‐Sverdlov · 2011 · Atherosclerosis
  76. Nonalcoholic fatty liver disease: from pathogenesis to patient care
    Gabriel Perlemuter, Amélie Bigorgne, Anne‐Marie Cassard, Sylvie Naveau · 2007 · Nature Clinical Practice Endocrinology &#38 Metabolism
  77. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
    Saeed Chashmniam, Seyed Reza Mirhafez, Maryam Dehabeh, Mitra Hariri, Mohsen Azimi–Nezhad, B. Fatemeh Nobakht M. Gh · 2019 · European Journal of Clinical Nutrition
  78. Nonalcoholic fatty liver disease
    Timothy Hardy, Quentin Mark Anstee, Christopher Paul Day · 2015 · Current Opinion in Gastroenterology
  79. Endocrine causes of nonalcoholic fatty liver disease
    Laura Marino · 2015 · World Journal of Gastroenterology
  80. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets
    Zobair M. Younossi, M. J. Reyes, Alita Mishra, R. Mehta, Linda L Henry · 2013 · Alimentary Pharmacology & Therapeutics
  81. Evaluation and management of non-alcoholic steatohepatitis
    Seela Ramesh, Arun Jayant Sanyal · 2004 · Journal of Hepatology
  82. A Current Understanding of Bile Acids in Chronic Liver Disease
    Naba Farooqui, Anshuman Elhence, S. Shalimar · 2021 · Journal of Clinical and Experimental Hepatology
  83. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation
    Yunjing Zhang, Runqiu Jiang, Xiaojiao Zheng, Sha Lei, Fengjie Huang, Guoxiang Xie, Sandi Alexander Kwee, Herbert Yu, Christine E. Farrar, Beicheng Sun et al. · 2019 · British Journal of Pharmacology
  84. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
    Traussnigg, Stefan, Schattenberg, Jörn M, Demir, Münevver, Wiegand, Johannes, Geier, Andreas, Teuber, Gerlinde, Hofmann, Wolf Peter, Kremer, Andreas E, Spreda, Frank, Kluwe, Johannes et al. · 2019 · The Lancet Gastroenterology & Hepatology
  85. Recent advances on FXR-targeting therapeutics
    Katrin Panzitt, Gernot Zollner, Hanns–Ulrich Marschall, Martin Wagner · 2022 · Molecular and Cellular Endocrinology
  86. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management
    Piero Portincasa, Ignazio Grattagliano, Vincenzo Ostilio Palmieri, Giuseppe Palasciano · 2004 · Clinical Biochemistry
  87. The metabolic syndrome and nonalcoholic fatty liver disease in children
    Shikha S. Sundaram, Philip Scott Zeitler, Kristen J. Nadeau · 2009 · Current Opinion in Pediatrics
  88. Therapy of nonalcoholic fatty liver disease: current status.
    Marko Duvnjak, Vedran Tomašić, Marija Gomerčić, Lea Smircic Duvnjak, Neven Baršić, Ivan Lerotić · 2009 · PubMed
  89. Perspectives on Treatment for Nonalcoholic Steatohepatitis
    Guillaume Lassailly, Robert J. Caiazzo, François N. Pattou, Philippe Mathurin · 2016 · Gastroenterology
  90. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease
    Anita Pathil, Jan Mueller, Arne Warth, Waleé Chamulitrat, Wolfgang Stremmel · 2011 · Hepatology
  91. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities
    Richard Radun, Michael Trauner · 2021 · Seminars in Liver Disease
  92. Pediatric non-alcoholic fatty liver disease: Preventive andtherapeutic value of lifestyle intervention
    Valério Nobili, Anna Alisi, Massimiliano Raponi · 2009 · World Journal of Gastroenterology
  93. Translating an Understanding of the Pathogenesis of Hepatic Fibrosis to Novel Therapies
    Don C. Rockey · 2013 · Clinical Gastroenterology and Hepatology
  94. Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets
    Jacob George, Christopher Liddle · 2007 · Molecular Pharmaceutics
  95. Specific bile acids inhibit hepatic fatty acid uptake in mice
    Biao Nie, Hyo Min Park, Melissa Kazantzis, Min Lin, Amy H. Henkin, Stephanie M. Ng, SuJin Song, Yu‐Li Chen, Heather Tran, Robin Lai et al. · 2012 · Hepatology
  96. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Galip Ersöz, Fulya Günşar, Zeki A. Karasu, Sinan Akay, Yücel Batur, Ulus Salih Akarca · 2005 · The Turkish Journal of Gastroenterology
  97. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
    M. Yu. Nadinskaia, Marina V. Maevskaya, Vladimir T Ivashkin, Kh. B. Kodzoeva, И. Ю. Пирогова, Chesnokov Ev, Nersesov Alexander Vitalevich, Jamilya A. Kaibullayeva, Akzhan Konysbekova, A. Raissova et al. · 2021 · World Journal of Gastroenterology
  98. Retracted: Natural course of nonalcoholic fatty liver disease in southern China: A prospective cohort study
    Yong Jian Zhou, Yu Yuan Li, Yu Qiang Nie, Chun‐Ming Huang, Chuang Yu Cao · 2011 · Journal of Digestive Diseases · Retracted
  99. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis
    Maria Luisa Balmer, Kathrin Siegrist, Arthur Zimmermann, Jean‐François Dufour · 2009 · Liver International
  100. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans
    Stefano Ballestri, Fabio Nascimbeni, Dante Romagnoli, Enrica Baldelli, Amedeo Lonardo · 2016 · Advances in Therapy